178 related articles for article (PubMed ID: 11758073)
1. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
[TBL] [Abstract][Full Text] [Related]
4. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
[TBL] [Abstract][Full Text] [Related]
5. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
[TBL] [Abstract][Full Text] [Related]
11. Earlier translation of evidence into public subsidy may prevent morbidity and mortality: an example using statins in diabetics with normal cholesterol levels.
Page MM; Sanfilippo FM; Geelhoed EA; Briffa TG; Hobbs MS
Aust N Z J Public Health; 2012 Oct; 36(5):435-40. PubMed ID: 23025364
[TBL] [Abstract][Full Text] [Related]
12. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Perreault S; Hamilton VH; Lavoie F; Grover S
Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
[TBL] [Abstract][Full Text] [Related]
13. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
14. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia.
Luke JN; Brown A; O'Neal DN; O'Dea K; Jenkins AJ; Kelaher M; Best JD; Rowley KG
Med J Aust; 2009 May; 190(10):552-6. PubMed ID: 19450200
[TBL] [Abstract][Full Text] [Related]
15. Statins: cost analysis in Indian scenario from eight major clinical trials.
Sanmukhani J; Shah V
J Postgrad Med; 2010; 56(3):196-200. PubMed ID: 20739765
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
Rahman M; Baimbridge C; Davis BR; Barzilay JI; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
Clin Nephrol; 2013 Oct; 80(4):235-48. PubMed ID: 23816477
[TBL] [Abstract][Full Text] [Related]
17. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
Forge BH; Briganti EM
Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
[TBL] [Abstract][Full Text] [Related]
18. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
